|
Characteristics of patients at the time of enrollment in the trials |
||||||
| Characteristic |
All Patients |
Supervision per day |
Dependence Level |
|||
| ≤ 12 hrs |
> 12 hrs |
< 3 |
≥ 3 |
|||
|
|
||||||
| Number |
1287 |
407 |
880 |
692 |
595 |
|
| Socio-demographic details |
||||||
| Age, (years) |
Mean (SD) |
73.8 (8.3) |
72.9 (8.5) |
74.2 (8.2)* |
72.1 (8.6) |
75.8 (7.5)* |
| Female |
N (%) |
801 (62) |
261 (64.1) |
540 (61.4) |
388 (56.1) |
413 (69.4)* |
| Education beyond elementary school |
N (%) |
876 (68.8) |
271 (67.6) |
605 (69.3) |
508 (74.1) |
368 (62.6)* |
| Lives with caregiver |
N (%) |
934 (74.2) |
203 (51.5) |
731 (84.5)* |
496 (73.0) |
438 (75.5) |
| Spouse or partner caregiver |
N (%) |
781 (62.1) |
175 (43.0) |
606 (68.9)* |
431 (62.3) |
350 (58.8) |
| Clinical characteristics |
||||||
| Time since onset of cognitive problems, (years) |
Mean (SD) |
3.8 (2.6) |
3.6 (2.6) |
3.9 (2.6)* |
3.7 (2.6) |
4.0 (2.6)* |
| Time since AD diagnosis (years) |
Mean (SD) |
1.0 (1.4) |
0.9 (1.2) |
1.1 (1.4) |
0.9 (1.3) |
1.1 (1.4)* |
| Extra-pyramidal symptoms |
N (%) |
68 (5.2) |
15 (3.7) |
53 (6.0) |
29 (4.2) |
39 (6.6) |
| Anti-psychotic medication |
N (%) |
328 (25.5) |
81 (19.9) |
247 (28.1)* |
134 (19.3) |
194 (32.6)* |
| MMSE |
Mean (SD) |
19.3 (3.7) |
20.4 (3.4) |
18.8 (3.8)* |
20.5 (3.3) |
18.0 (3.8)* |
| ADAS-cog |
Mean (SD) |
25.4 (10.4) |
22.7 (9.7) |
26.7 (10.5)* |
22.0 (8.7) |
29.5 (10.8)* |
| Dependence |
||||||
| Dependence level >= 3 |
N (%) |
583 (46.0) |
134 (32.9) |
461 (52.4) |
||
| DAD |
Mean (SD) |
70.1 (22.5) |
77.7 (20.0) |
66.7 (22.7)* |
81.9 (14.9) |
56.3 (22.0)* |
|
* Statistically significant difference between groups (p = 0.05). | ||||||
Caro et al. BMC Neurology 2002 2:6 doi:10.1186/1471-2377-2-6 |
||||||